Following the Holiday, there is an Urgent Need for Platelet Donations. Please Donate Now!
- Give Blood
- Why Give
- Get Involved
- Our Impact
- View Promotions
Orlando, Florida
September 8, 2014
OneBlood, Inc., a not-for-profit blood center based in Florida, through a wholly owned subsidiary, is expanding into new avenues within the biotech industry and announced it is partnering with and investing in iSpecimen, a provider of on-demand human biospecimens to the life science community.
“We have entered a new era of blood banking and it demands a progressive and forward thinking approach. By being proactive and investing in new and emerging technologies and platforms of service today, we enhance our ability to further develop avenues that provide additional cost savings to our hospital partners and their patients”
-Bud Scholl, Chief Strategy and Integration Officer
OneBlood
iSpecimen brings together sophisticated technology and professional service solutions to meet the needs of today’s medical research community. The company provides customized specimen collections, along with clinical data, to help researchers increase the speed of bringing new drugs and diagnostics to market. OneBlood, in conjunction with existing investors, will help grow iSpecimen’s healthcare partner network and scale operations to meet the ever increasing needs of its research customers for annotated human biospecimens.
“The synergies between OneBlood and iSpecimen are plentiful. Both organizations are developing cutting-edge advances in medical science and opening the door to innovative clinical research. These realities make the partnership between the two organizations a natural one,” said Scholl.
“This is an incredibly exciting time in the evolution of iSpecimen. Since raising our first round of financing we’ve expanded our partner network to include dozens of healthcare facilities, implemented our technology and proven that it can match researchers’ needs to available specimens,” said Christopher Ianelli, MD, PhD, Founder and Chief Executive Officer of iSpecimen. “We have introduced the idea of using technology to connect researchers to specific patients and their specimens and are thrilled that OneBlood, along with our existing investors, believes in iSpecimen’s vision. We look forward to their invaluable strategic guidance as we expand our operations to provide specimens to even more researchers worldwide,” said Ianelli.
Founded in 2009, iSpecimen is a pioneer in the use of technology to search electronic health records along with laboratory information systems to find specific patients and specimens in order to repurpose them into research. The company currently provides access to millions of patients and their discarded specimens yearly to its customers in industry, government and academia.
To learn more about OneBlood please visit www.oneblood.org. To learn more about iSpecimen please visit www.iSpecimen.com.